Practical Dermatology

04/01/2022

Third Annual San Diego Dermatology Symposium (SDDS) Takes Place in Person - Practical Dermatology

Held for the first time in-person at the Hilton San Diego Bayfront, the Third Annual San Diego Dermatology Symposium (SDDS, March 11-13, 2022) offered networking, learning, and winning giveaways. Many attendees shared that this was their first live in-person meeting in a couple of years. Check out some highlights from the presentations https://hubs.ly/Q017dtkJ0

By Caroline Tan, MD, UCLA Dermatology Resident, PGY3 Held for the first time in-person at the Hilton San Diego Bayfront, the Third Annual San

03/31/2022

Check out some of our latest videos: AD Treatment Guidelines; Cosmetic Derm Updates; Post-Resurfacing Care; Treating Nails; Choosing the Right Biologic. Get treatment pearls for medical dermatology and aesthetic patients from leading dermatologists: https://practicaldermatology.com/meeting-coverage/aad-2022/laser-focus-optimizing-patient-care-for-best-results?c4src=meeting-coveragein-this-series

#dermatology #practicaldermatology #AAD2022 #eczema #psoriasis #aesthetics #nails #skinhealth #skincare

03/29/2022

Practical Dermatology

Did you attend the #AAD2022 Annual Meeting in Boston? There were so many great sessions and lots of interesting news. What was your favorite session?
Be sure to check out all of our coverage of the meeting https://hubs.ly/Q016_mG60

#dermatology #practicaldermatology #AAD2022 #AAD #dermatologynews

Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology.

03/28/2022

Lilly's Olumiant Associated with Significant Hair Growth in Patients with Severe Alopecia Areata - Practical Dermatology

Olumiant (baricitinib) from Eli Lilly and Company produced significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks, with nearly 75% of those who responded to Olumiant 4mg achieving 90% scalp coverage. The 52-week pooled findings were presented at the #AAD2022 Annual Meeting. FDA last month granted priority review for Olumiant as a potential first-in-disease medicine for severe #alopecia areata. https://hubs.ly/Q016XhtT0

Olumiant® (baricitinib) from Eli Lilly and company produced significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks, with nearly 75

03/28/2022

Aquavit Submits NDA for New Neurotoxin - Practical Dermatology

Aquavit Pharmaceuticals Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the #FDA for approval. The company also unveiled it Dermatox and Microtox programs at the #AAD22 Annual Meeting. https://hubs.ly/Q016VwWc0

Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled it Dermatox

03/28/2022

Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Study - Practical Dermatology

New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura) in adolescent and adult patients with nonsegmental #vitiligo show that twice daily application was associated with clinically meaningful facial and total body repigmentation. Presented in a late-breaking abstract session at the #AAD22 Annual Meeting, the data show a greater proportion of treated patients reached the facial and total body Vitiligo Area Scoring (F-VASI and T-VASI, respectively) endpoints at Week 52. https://hubs.ly/Q016VwW80

New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opze

03/28/2022

Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis - Practical Dermatology

UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque #psoriasis at the #AAD22 Annual Meeting, including a late breaking oral platform presentation and 10 posters. The platform presentation detailed new analysis of pooled data from five bimekizumab Phase 3/3b clinical trials, which showed that more than 80 percent of patients who achieved PASI 100 at week 16 and entered the open-label extension studies maintained this response through two years, and no new safety signals were identified. https://hubs.ly/Q016Vs1H0

UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatol

03/28/2022

Dupixent Performs Well in Phase 3s for Prurigo Nodularis - Practical Dermatology

Detailed positive results from the Phase 3 PRIME2 trial show Dupixent (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. #AAD22 https://hubs.ly/Q016V7Xt0

Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared

03/28/2022

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 AAD Annual Meeting - Practical Dermatology

Krystal Biotech Inc., presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), at the #AAD22 Annual Meeting in Boston. https://hubs.ly/Q016V1J20

Krystal Biotech, Inc., presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene

03/26/2022

Get to Know Allergan Aesthetics’ Allē Flash - Practical Dermatology

Allergan Aesthetics, an AbbVie company, is offering a new in-office rewards delivery system through its consumer loyalty program, Allē—Allē Flash.
With a simple scan of a QR code at any participating provider’s office, Allē Members get the chance to be rewarded in real time as they check in for existing appointments at their participating provider’s office. https://hubs.ly/Q016R5ZK0

Allergan Aesthetics, an AbbVie company, is offering a new in-office rewards delivery system through its consumer loyalty program, Allē&md

03/26/2022

TMB-001, a topical isotretinoin formulated using Timber Pharmaceuticals’ patented IPEG™ delivery system, shows benefit in the treatment of congenital ichthyosis (CI), regardless of the subtype. Findings are being presented in a late-breaking presentation of a sub-analysis of the Phase 2b CONTROL study presented by Christopher Bunick, MD, PhD at the #AAD2022 Annual Meeting in Boston. https://hubs.ly/Q016QXQj0

03/26/2022

Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Tx - Practical Dermatology

Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Sun Pharma's WINLEVI (clascoterone) cream 1% in patients with #acne aged 12 years and older. The findings were presented at the #AAD2022 Annual Meeting in Boston. https://hubs.ly/Q016Q_-50

The new data supports therapeutic rationale for first-in-class androgen receptor inhibitor.

03/26/2022

Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Years - Practical Dermatology

Interim data support the long-term safety and efficacy profile of Adbry (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a poster presentation at the #AAD2022 Annual Meeting. #eczema
https://hubs.ly/Q016Q_YC0

Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate

03/26/2022

Tremfya Safe, Effective Across Broad Patient Subpopulations Through Five Years: Analysis - Practical Dermatology

Tremfya (guselkumab) from the Janssen Pharmaceutical Companies Of Johnson & Johnson provides a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque #psoriasis (PsO), based on an analysis of data from Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials. #AAD2022 https://hubs.ly/Q016QZb30

Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson provides a consistent, high degree of durable skin c

03/26/2022

Galderma Launches Twyneo in the US - Practical Dermatology

Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. Twyneo Cream features patented microencapsulation technology that allows the delivery of two ingredients that have not been previously combined and enables their controlled release. It is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial #acne. #AAD2022 https://hubs.ly/Q016QX0B0

Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. The launch takes place during the annual meeting of the Americ

03/26/2022

RedDress Ships ActiGraft to Ukraine to Treat Civilian Casualties - Practical Dermatology

RedDress has begun shipments of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of Russian attacks. An initial shipment of 400 units of the blood clotting wound care system is en route. https://hubs.ly/Q016Q-Hd0

RedDress has begun shipments of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as

03/25/2022

New issue alert! Check out the latest issue of Practical Dermatology - now available online! Get updates on the state of practice in dermatology—from advocacy to M&A activity to emerging qualifications. Plus, tips on improving patient care. https://hubs.ly/Q016PldT0

#dermatology #practicaldermatology #newissue #newcontent #stateofdermatology #weekendreading

03/25/2022

Excited to be at #aad2022 -stay tuned for our coverage of the meeting and new video series coming soon!

03/25/2022

Mark D. Kaufmann, MD, FAAD Takes the Helm at AAD - Practical Dermatology

Long-time Practical Dermatology® Digital Practice editor Mark D. Kaufmann, MD, FAAD, is the new President of the American Academy of Dermatology.
Dr. Kaufmann, a clinical professor of the Department of Dermatology Icahn School of Medicine at Mount Sinai in New York, will begin his one-year term immediately following the #AAD2022 annual; meeting, which takes place in Boston from March 25 – 29.
https://hubs.ly/Q016NDrS0

New officers, board members announced at AAD annual meeting

03/25/2022

Are you attending #aad2022? Visit us at Booth 2223

03/25/2022

The FDA has cleared granted 510(k) clearance to Cutera's AviClear acne device.
This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne.
AviClear targets acne at the source by selectively targeting the sebocytes and suppressing sebum production. In addition to reducing existing acne, clinical trials show that future breakout episodes are shorter, less intense, and more infrequent following the AviClear procedure.
https://hubs.ly/Q016MWPd0

#dermatology #practicaldermatology #acne #FDAapproval #AviClear

03/23/2022

New AAD, Industry Collab to Increase Number of Black, Latino, and Indigenous Physicians in Dermatology - Practical Dermatology

The American Academy of Dermatology (AAD) in collaboration with Johnson & Johnson Consumer Health and the Janssen Pharmaceutical Companies Of Johnson & Johnson is launching “Pathways: Inclusivity in Dermatology” to increase the number of practicing dermatologists in the US who are from the Black, Latino, and Indigenous communities, which are underrepresented minorities (URM) in medicine. The plan is to double representation in next 5 years. Learn what steps they're taking: https://hubs.ly/Q016BwSh0

#dermatology #practicaldermatology #AAD2022 #DEI #diversityinmedicine #inclusion

“Pathways: Inclusivity in Dermatology” aims to increase the number of practicing dermatologists in the U.S. who are from the Black, Latino, and Indigenous communities, which are underrepresented minorities in medicine.

03/22/2022

DefenAge Receives Two US Patents For Melasma and Hair Growth - Practical Dermatology

The US Patent and Trademark Office has granted two new patents to DefenAge Skincare for the use of Defensin-molecules for topical treatment of hair loss in skin affected by #alopecia and of the hyperpigmented lesions of #melasma https://hubs.ly/Q016wdVb0

The US Patent and Trademark Office has granted two new patents to Defanage Skincare for the use of Defensin-molecules for topical treat

03/22/2022

Dove, Crown Coalition Applaud U.S. House of Representatives for Passing Crown Act - Practical Dermatology

Dove, Crown Coalition Applaud U.S. House of Representatives for Passing Crown Act:
The CROWN Act legislation (H.R. 2116) provides legal protection from hair discrimination based on the texture of natural hair or hairstyles such as braids, locs, twists, bantu knots, and Afros. https://hubs.ly/Q016rSGZ0

The CROWN Act legislation (H.R. 2116) provides legal protection from hair discrimination based on the texture of natural hair or hairstyles such as braids, locs, twists, bantu knots, and Afros.

03/22/2022

Mount Sinai Health System Launches Alopecia Areata Center of Excellence - Practical Dermatology

In an effort to deliver outstanding comprehensive care and to employ revolutionary approaches to novel therapeutics around alopecia areata, the Mount Sinai Health System has launched the Alopecia Areata Center of Excellence. Under the leadership of Director Emma Guttman-Yassky, MD, PhD, the new Center will be fully integrated within the state-of-the art Laboratory for Inflammatory Skin Diseases, and will fall under the umbrella of the Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai.
The creation of this new Alopecia Areata Center of Excellence was made possible by a generous $5 million gift from the Pure Family.
https://hubs.ly/Q016rMyK0

The creation of the new Alopecia Areata Center of Excellence was made possible by a generous $5 million gift from the Pure Family.

03/21/2022

Study: Laser Surgery Lawsuits Less Likely with Physician Operators - Practical Dermatology

The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery.
Researchers analyzed cases of liability claims due to a cutaneous laser surgery device that took place in the United States from 2012 to 2020 and found that 71 percent of 69 claims involved a non-physician operator. Laser hair removal was most litigated (44 cases, 64%), followed by laser skin rejuvenation (20 cases, 30%), the study showed.
https://hubs.ly/Q016mtRZ0

Fully 71 percent of 69 liability claims due to a cutaneous laser surgery device involved a non-physician operator.